Guggenheim initiated coverage on ANI Pharma with a new price target
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $55.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/11/2024 | $68.00 | Overweight | Piper Sandler |
| 3/15/2024 | $80.00 | Overweight | CapitalOne |
| 8/22/2023 | $60.00 → $73.00 | Buy | H.C. Wainwright |
| 3/1/2023 | $55.00 | Buy | Guggenheim |
| 9/7/2022 | $50.00 | Buy | H.C. Wainwright |
| 11/2/2021 | $60.00 → $65.00 | Outperform | Raymond James |
| 11/2/2021 | $70.00 | Buy | Truist |
Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-yearNet loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 millionDiluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1.34Completed the acquisition of Alimera Sciences, Inc. on September 16, 2024, adding two commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioImplemented new capital structure that is expected to reduce interest expense by approximately $39.0 million on an annualized basis (1)Inc
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows: • The Guggenheim Inaugural Healthcare Innovation Conference Wednesday, November 13, 2024, at 10:00am ET • The Jefferies London Healthcare Conference Wednesday, November 20, 2024, at 2:30pm GMT/9:30am ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay
PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, November 8, 2024 Time8:00 a.m. ET Toll free (U.S.)800-445-7795 Conference ID4757982 Webcast (live and replay)www.anipharmaceuticals.com, under the "Investors" section A replay of the c
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
10-Q - ANI PHARMACEUTICALS INC (0001023024) (Filer)
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)
Piper Sandler initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $68.00
CapitalOne initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $80.00
H.C. Wainwright reiterated coverage of ANI Pharma with a rating of Buy and set a new price target of $73.00 from $60.00 previously
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Powder. ANI's L-Glutamine Oral Powder is the generic version of the reference listed drug (RLD) Endari®. "The approval and launch of L-Glutamine Oral Powder, the first AA-rated approved generic to Endari®, continues to demonstrate the strong capabilities and execution of our R&D team. We remain focused on ensuring that patients in need, and the providers who care for them, have access to our high-quality therapeutics," stated Nikhil Lalwani, Presiden
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup raised the price target for NVIDIA Corporation (NASDAQ:NVDA) from $126 to $150. Citigroup analyst Atif Malik maintained a Buy rating. NVIDIA shares gained 6.8% to close at $126.09 on Tuesday. See how other analysts view this stock. Truist Securities raised the price target for Rivian Automotive, Inc. (NASDAQ:RIVN) from $10 to $13. Truist Securities analyst Jordan Levy maintained a Hold rating. Rivian Automotive shares gained 8.6% to close at $11.96 on Tuesday. See how other analysts view
Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-yearNet loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 millionDiluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1.34Completed the acquisition of Alimera Sciences, Inc. on September 16, 2024, adding two commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioImplemented new capital structure that is expected to reduce interest expense by approximately $39.0 million on an annualized basis (1)Inc
PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, November 8, 2024 Time8:00 a.m. ET Toll free (U.S.)800-445-7795 Conference ID4757982 Webcast (live and replay)www.anipharmaceuticals.com, under the "Investors" section A replay of the c
Generated record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4%, and record Rare Disease net revenues of $49.2 million, an increase of 102.4% year-over-yearDelivered adjusted non-GAAP EBITDA of $33.2 million, and adjusted non-GAAP diluted earnings per share of $1.02Net loss available to common shareholders of $(2.7) million and diluted GAAP loss per share of $(0.14)On track to close acquisition of Alimera Sciences, Inc. in the third quarter of 2024, adding two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioIncreased 2024 guidance with expected net revenues of $540 million to $560 million, adj
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
-- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Meredith W. Cook will join the Company as SVP, General Counsel and Corporate Secretary, effective July 18. Ms. Cook brings over 20 years of legal and leadership experience in specialty and generics pharmaceuticals, including in corporate governance, mergers and acquisitions (M&A), strategic transactions, and intellectual property (IP). "We are delighted to welcome Ms. Cook to our leadership team. Meredith is an accomplished attorney with demonstrated leadership and expertise in the pharmaceutical industry and will no doubt play an important role in the Company's continued growth. Her guidance and perspectives
Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling
Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling
Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling